The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus

Cancer Biology and Therapy

Volumn 10, Issue 3, 2010, Pages 242-250

  Xiao, Lian Li ^a   Wu, Yu Mei ^b   Qian, Jing ^a   Tan, Yuan ^a   Xie, Guo Liang ^a   Zhang, Kang Jian ^b   Wang, Yi Gang ^a   Jia, Xiao Yuan ^a   Liu, Xin Yuan ^a,b  

^a ZHEJIANG SCI TECH UNIVERSITY   (China)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

Antitumor effect; IL 24; NCI H460 lung carcinoma; Survivin promoter; Triple regulated oncolytic adenovirus

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ACTIN; CASPASE; CASPASE 8; CRYSTAL VIOLET; E1A PROTEIN; E1B PROTEIN; INTERLEUKIN 24; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ONCOLYTIC ADENOVIRUS; ONYX 015; RETINOBLASTOMA PROTEIN; SURVIVIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SIZE; CELL STRUCTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; GENE DELETION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LUNG CARCINOMA; MOUSE; NONHUMAN; NUDE MOUSE; PROMOTER REGION; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 77955498537     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.3.12308     Document Type: Article

References (40)

1. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001; 7:781-7. (Pubitemid 32691631)
2. Kirn D. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert opinion on biological therapy 2001; 1:525-38.
3. O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer cell 2004; 6:611-23.
4. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces antiglioma effect in vivo. Oncogene 2000; 19:2-12.
5. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nature medicine 2000; 6:1134-9.
6. Goodrum FD, Ornelles DA. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. Journal of virology 1998; 72:9479-90.
7. Howe JA, Demers GW, Johnson DE, Neugebauer SE, Perry ST, Vaillancourt MT, et al. Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy. Mol Ther 2000; 2:485-95.
8. Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, zur Hausen H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. Journal of virology 1998; 72:9470-8. (Pubitemid 28520810)
9. Fukuda K, Abei M, Ugai H, Seo E, Wakayama M, Murata T, et al. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer. Cancer research 2003; 63:4434-40.
10. Gomez-Manzano C, Balague C, Alemany R, Lemoine MG, Mitlianga P, Jiang H, et al. A novel E1A-E1B mutant adenovirus induces glioma regression in vivo. Oncogene 2004; 23:1821-8.
11. Fukuda K, Abei M, Ugai H, Kawashima R, Seo E, Wakayama M, et al. E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer. Cancer gene therapy 2009; 16:126-36.
12. Liu XY, Gu JF. Targeting gene-virotherapy of cancer. Cell research 2006; 16:25-30.
13. Pei Z, Chu L, Zou W, Zhang Z, Qiu S, Qi R, et al. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 2004; 39:1371-81. (Pubitemid 38569059)
14. Zhang Z, Zou W, Wang J, Gu J, Dang Y, Li B, et al. Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble Flt-1. Mol Ther 2005; 11:553-62.
15. Zhang ZL, Zou WG, Luo CX, Li BH, Wang JH, Sun LY, et al. An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell research 2003; 13:481-9.
16. Yang M, Cao X, Yu MC, Gu JF, Shen ZH, Ding M, et al. Potent antitumor efficacy of ST13 for colorectal cancer mediated by oncolytic adenovirus via mitochondrial apoptotic cell death. Human gene therapy 2008; 19:343-53.
17. Zhang Y, Gu J, Zhao L, He L, Qian W, Wang J, et al. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy. Cancer research 2006; 66:4291-8.
18. Zhao L, Gu J, Dong A, Zhang Y, Zhong L, He L, et al. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Human gene therapy 2005; 16:845-58. (Pubitemid 40982333)
19. Zhang KJ, Wang YG, Cao X, Zhong SY, Wei RC, Wu YM, et al. Potent antitumor effect of interleukin-24 gene in the survivin promoter and retinoblastoma double-regulated oncolytic adenovirus. Human gene therapy 2009; 20:818-30.
20. Fisher PB. Is mda-7/IL-24 a "magic bullet" for cancer? Cancer research 2005; 65:10128-38.
21. Gupta P, Su ZZ, Lebedeva IV, Sarkar D, Sauane M, Emdad L, et al. mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacology & therapeutics 2006; 111:596-628.
22. Saeki T, Mhashilkar A, Chada S, Branch C, Roth JA, Ramesh R. Tumor-suppressive effects by adenovirus-mediated mda-7 gene transfer in non-small cell lung cancer cell in vitro. Gene therapy 2000; 7:2051-7.
23. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature medicine 1997; 3:917-21. (Pubitemid 27353455)
24. Nouraee N, Mowla SJ, Ozhand A, Parvin M, Ziaee SA, Hatefi N. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker. Urology journal 2009; 6:101-8.
25. Song KY, Jung CK, Park WS, Park CH. Expression of the antiapoptosis gene Survivin predicts poor prognosis of stage III gastric adenocarcinoma. Japanese journal of clinical oncology 2009; 39:290-6.
26. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proceedings of the National Academy of Sciences of the United States of America 2002; 99:4349-54.
27. Rodel C, Haas J, Groth A, Grabenbauer GG, Sauer R, Rodel F. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. International journal of radiation oncology, biology, physics 2003; 55:1341-7.
28. Virrey JJ, Guan S, Li W, Schonthal AH, Chen TC, Hofman FM. Increased survivin expression confers chemoresistance to tumor-associated endothelial cells. The American journal of pathology 2008; 173:575-85.
29. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. The Biochemical journal 1999; 344:305-11. (Pubitemid 30011584)
30. Kamizono J, Nagano S, Murofushi Y, Komiya S, Fujiwara H, Matsuishi T, et al. Survivin-responsive conditionally replicating adenovirus exhibits cancer-specific and efficient viral replication. Cancer research 2005; 65:5284-91.
31. Zheng X, Rao XM, Snodgrass C, Wang M, Dong Y, McMasters KM, et al. Adenoviral E1a expression levels affect virus-selective replication in human cancer cells. Cancer biology & therapy 2005; 4:1255-62.
32. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008; 14:5000-5.
33. Paduano F, Villa R, Pennati M, Folini M, Binda M, Daidone MG, et al. Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Molecular cancer therapeutics 2006; 5:179-86.
34. Shen C, Buck A, Polat B, Schmid-Kotsas A, Matuschek C, Gross HJ, et al. Triplex-forming oligodeoxynucleotides targeting survivin inhibit proliferation and induce apoptosis of human lung carcinoma cells. Cancer gene therapy 2003; 10:403-10.
35. Ling X, Li F. Silencing of antiapoptotic survivin gene by multiple approaches of RNA interference technology. BioTechniques 2004; 36:450-4. (Pubitemid 38299059)
36. Zeis M, Siegel S, Wagner A, Schmitz M, Marget M, Kuhl-Burmeister R, et al. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol 2003; 170:5391-7.
37. Sauane M, Gupta P, Lebedeva IV, Su ZZ, Sarkar D, Randolph A, et al. N-glycosylation of MDA-7/IL-24 is dispensable for tumor cell-specific apoptosis and "bystander" antitumor activity. Cancer research 2006; 66:11869-77.
38. Sarkar D, Su ZZ, Lebedeva IV, Sauane M, Gopalkrishnan RV, Dent P, et al. mda-7 (IL-24): signaling and functional roles. BioTechniques 2002; 30-9.
39. Su Z, Emdad L, Sauane M, Lebedeva IV, Sarkar D, Gupta P, et al. Unique aspects of mda-7/IL-24 antitumor bystander activity: establishing a role for secretion of MDA-7/IL-24 protein by normal cells. Oncogene 2005; 24:7552-66.
40. Sauane M, Su ZZ, Gupta P, Lebedeva IV, Dent P, Sarkar D, et al. Autocrine regulation of mda-7/IL-24 mediates cancer-specific apoptosis. Proceedings of the National Academy of Sciences of the United States of America 2008; 105:9763-8.